Haemoglobin A1c Testing Devices Market Size, Growth and Forecast 2032

Hemoglobin A1c (HbA1c) Testing Devices Market Overview:

The hemoglobin A1c testing devices market was valued at $1.80 billion in 2018, increased to $2.26 billion in 2024 and is anticipated to reach $3.70 billion by 2032, at a CAGR of 6.44% during the forecast period.

Hemoglobin A1c (HbA1c) Testing Devices Market Insights

• The hemoglobin A1c testing devices market was valued at $2.26 billion in 2024 and is projected to reach $3.70 billion by 2032, registering a CAGR of 6.44% during the forecast period.
• The market reflects increasing adoption of HbA1c testing across diabetes management programs, driven by rising diagnostic awareness, stronger preventive healthcare initiatives and greater utilization of both laboratory-based testing devices and point-of-care systems, with laboratory-based testing devices holding a 63.2% share in 2024.
• Market drivers include growing global diabetes prevalence, expansion of clinical screening volumes and technological advancements that improve accuracy, automation and connectivity of HbA1c testing platforms across hospitals, diagnostic laboratories and homecare environments.
• Major players focus on product innovation, assay precision and platform integration, while cost sensitivity and access gaps in developing regions continue to act as key restraints on wider testing adoption.
• North America leads with a 31.4% share in 2024, followed by Europe with a 28.6% share and Asia-Pacific with a 25.7% share, reflecting strong testing penetration and expanding healthcare infrastructure across high-growth economies.

Hemoglobin A1c (HbA1c) Testing Devices Market Segmentation Analysis

By type of device

The hemoglobin A1c testing devices market by type of device is led by laboratory-based testing devices, which accounted for a 63.2% market share in 2024, driven by high analytical accuracy, strong adoption in centralized diagnostic infrastructures and widespread use in routine diabetes monitoring programs. Healthcare providers prefer laboratory analyzers due to superior throughput and standardized testing protocols that support large-volume screening. Point-of-care testing devices continue to gain traction, supported by rising demand for rapid HbA1c results, decentralized testing in outpatient settings and increasing deployment across primary care and physician-office laboratories.

• Trivitron Healthcare's NANO H5, a compact automated HPLC analyzer using ion-exchange chromatography, reports HbA1c results in under 130 seconds while processing five samples at a time with barcode scanning for identification.

By end use

Hospitals and clinics emerged as the dominant end-use segment with a 47.5% market share in 2024, supported by strong patient inflow, integrated diabetes management programs and growing adoption of HbA1c screening for routine glycemic control assessments. The presence of advanced diagnostic setups and reimbursement support further strengthens demand in this segment. Diagnostic laboratories represent a significant secondary user base, while homecare settings and others continue expanding due to increasing popularity of self-testing solutions and growing emphasis on personalized chronic disease monitoring.

• Siemens Healthineers' DCA Vantage Analyzer enables rapid HbA1c testing from one microliter of whole blood, delivering results in six minutes to support point-of-care glycemic monitoring during patient visits in hospital settings.

By Technology

The market by technology is dominated by high-performance liquid chromatography, which recorded a 42.6% market share in 2024, driven by its superior precision, strong clinical reliability and global recognition as the reference standard for HbA1c quantification. The technology remains widely preferred in accredited laboratories and hospital diagnostic centers. Immunoassays and enzymatic assays are gaining adoption due to operational simplicity and cost-efficient testing workflows, while boronate affinity chromatography and others support niche clinical applications and specialized diagnostic environments.

Key Growth Drivers

Rising global diabetes prevalence and increased screening volume

The hemoglobin A1c testing devices market grows significantly due to the rapid increase in diabetes incidence worldwide and rising emphasis on routine glycemic monitoring. Healthcare systems are strengthening chronic disease surveillance programs, which drives higher adoption of HbA1c testing for diagnosis, prognosis and long-term glucose control assessment. National diabetes screening initiatives, expanding insurance coverage for diagnostic testing and growing patient awareness about early detection further accelerate device utilization. The shift from episodic glucose testing to continuous metabolic risk assessment reinforces sustained demand for both laboratory and point-of-care HbA1c testing platforms across clinical and primary care environments.

• Abbott's Afinion analyzer delivers HbA1c results in minutes from a fingerstick sample, enabling immediate coachable moments during physician consultations. Independent studies confirm its coefficient of variation at 2.0% or less in NGSP units, supporting reliable screening and monitoring in busy primary care settings.

Expansion of point-of-care testing and decentralized diagnostics

The market experiences strong growth from increasing deployment of point-of-care HbA1c testing devices across outpatient facilities, physician offices and community-based care settings. Healthcare providers prioritize rapid turnaround time, patient-centric testing workflows and real-time treatment decision support, strengthening demand for compact, automated analyzers. The adoption of decentralized diagnostic models in remote and underserved regions enhances accessibility to diabetes monitoring services. Technological advancements such as user-friendly interfaces, cartridge-based systems and minimal sample-volume requirements improve device usability, supporting broader acceptance among clinicians and patients. This trend aligns with the transition toward preventive care and value-based healthcare delivery frameworks.

• Abbott's Afinion 2 analyzer deploys in physician offices and community pharmacies, delivering HbA1c results from fingerstick samples in minutes to enable immediate patient coaching and reduce follow-up visits.

Technological advancements and integration with digital health ecosystems

The market benefits from continuous technological innovation, including enhanced assay sensitivity, improved analytical precision and automation of testing workflows. Manufacturers increasingly integrate connectivity features, enabling seamless data transfer to electronic health records and remote monitoring platforms. The adoption of cloud-enabled reporting, interoperable diagnostic networks and AI-supported clinical decision tools strengthens the role of HbA1c testing in longitudinal diabetes management. These innovations support personalized therapy optimization, physician-patient collaboration and population-level disease analytics. As healthcare providers modernize diagnostic infrastructure, advanced HbA1c testing technologies gain strategic importance in clinical outcome improvement initiatives.

Key Trends and Opportunities

Growing adoption of home-based and self-testing HbA1c solutions

A major opportunity arises from the increasing acceptance of home-based testing solutions, supported by the rise of telehealth, remote patient monitoring and consumer-driven wellness models. Patients with chronic metabolic disorders increasingly prefer convenient testing outside clinical facilities, encouraging development of portable and easy-to-use HbA1c devices. Digital health platforms enable clinicians to remotely track results and adjust treatment plans, strengthening continuity of care. Expanding e-commerce distribution, subscription-based testing kits and partnerships between diagnostics companies and telemedicine providers create new revenue pathways and accelerate patient engagement in long-term diabetes management.

• Labcorp's Diabetes Risk (HbA1c) at-home collection kit uses Weavr Velvet technology for dried blood sampling, achieving over 97% accuracy compared to standard blood draws.

Advancements in high-sensitivity assays and multiparametric diagnostic platforms

The market witnesses an emerging trend toward high-sensitivity HbA1c assays and integrated diagnostic platforms that combine HbA1c testing with complementary biomarkers for metabolic risk profiling. Innovations in chromatographic and enzymatic methodologies enhance analytical reliability, while compact analyzers support multi-parameter testing within a single device. Research initiatives focus on improving standardization across testing methods to support global clinical harmonization. These advancements enable earlier detection of glycemic dysregulation, support therapeutic stratification and strengthen outcome-based clinical programs.

• Beckman Coulter's HbA1c Advanced assay on DxC 700 AU analyzers achieves total precision of 2% CV or less and shows clinically insignificant interference from common hemoglobin variants.

Key Challenges

Variability in test accuracy and standardization across testing methods

A key challenge arises from variability in test accuracy across different assay platforms and laboratory environments. Differences in calibration standards, device performance and analytical interpretation may affect reliability in clinical decision-making. Healthcare providers require strict adherence to international certification frameworks and quality-control programs to ensure consistent results. Resource-constrained settings may face operational limitations in maintaining standardized testing procedures. This challenge underscores the need for continuous validation, professional training and regulatory alignment to support uniform clinical outcomes and strengthen confidence in HbA1c-based glycemic assessment.

High device and testing costs in low- and middle-income healthcare systems

Cost remains a significant restraint, particularly in developing healthcare economies where limited reimbursement coverage and budget constraints restrict adoption of advanced HbA1c testing technologies. High procurement costs for analyzers, recurring expenditure on consumables and maintenance requirements pose financial barriers for smaller clinics and community care centers. Patients in low-income regions may face affordability challenges for routine HbA1c monitoring, affecting test penetration and long-term disease management outcomes. Addressing this challenge requires scalable pricing models, localized manufacturing strategies and public-health partnerships to expand access in underserved populations.

Regional Analysis

North America

North America accounted for a 31.4% market share in 2024 and continues to expand at a CAGR of 6.4% during the forecast period. The regional market increased from $766.80 million in 2018 to $952.20 million in 2024 and is projected to reach $1.56 billion by 2032, supported by strong diagnostic infrastructure, high diabetes screening volumes and widespread adoption of both laboratory-based and point-of-care testing platforms. Favorable reimbursement frameworks, expanding preventive care programs and increasing integration of digital diagnostic networks further strengthen HbA1c testing utilization across hospitals and clinical laboratories.

Europe

Europe held a 28.6% market share in 2024 and is expected to grow at a CAGR of 5.7%, reflecting sustained investments in standardized diabetes monitoring systems and widespread implementation of national screening frameworks. The market value rose from $457.20 million in 2018 to $550.58 million in 2024 and is forecast to reach $851.06 million by 2032. High adoption of HPLC-based laboratory analyzers, expanding primary-care testing capacity and strong regulatory emphasis on diagnostic quality assurance continue to support demand growth. Aging population trends and rising prevalence of metabolic disorders further reinforce HbA1c testing penetration across European healthcare networks.

Asia-Pacific

Asia-Pacific captured a 25.7% market share in 2024 and represents the fastest-growing region, expanding at a CAGR of 8.0% driven by rapid diabetes incidence growth, urbanization-driven lifestyle changes and increasing access to diagnostic services. The market grew from $366.30 million in 2018 to $484.11 million in 2024 and is expected to reach $891.99 million by 2032. Government-led screening initiatives, expanding private healthcare infrastructure and rising deployment of cost-efficient point-of-care analyzers support strong market expansion. Strengthening awareness of early glycemic assessment and localization of manufacturing and distribution capabilities further enhance adoption across emerging economies in the region.

Latin America

Latin America accounted for a 7.2% market share in 2024 and is projected to grow at a CAGR of 5.4%, supported by gradual modernization of diagnostic capabilities and increasing focus on chronic disease surveillance. The regional market value rose from $111.60 million in 2018 to $138.65 million in 2024 and is expected to reach $210.66 million by 2032. Demand is driven by hospitals and private laboratories, while growing penetration of point-of-care devices enhances accessibility in outpatient and community health environments. Expanding insurance coverage and strengthening public-health screening initiatives continue to support progressive market development.

Middle East

The Middle East represented a 4.1% market share in 2024 and is expected to expand at a CAGR of 4.9%, driven by rising prevalence of lifestyle-related metabolic conditions and increasing investments in advanced diagnostic infrastructure. The market grew from $61.20 million in 2018 to $71.36 million in 2024 and is projected to reach $104.11 million by 2032. Demand is concentrated in GCC countries, where large multispecialty hospitals and diagnostic centers are expanding HbA1c testing capacity. Growth is further supported by government-led screening initiatives, technology upgrades and rising adoption of automated and connected testing platforms.

Africa

Africa accounted for a 3.0% market share in 2024 and is projected to grow at a CAGR of 3.9%, reflecting progressive improvements in healthcare accessibility and expanding awareness of diabetes screening. The regional market value increased from $36.90 million in 2018 to $61.67 million in 2024 and is expected to reach $86.57 million by 2032. Adoption remains stronger in urban hospitals and reference laboratories, while decentralized testing models supported by portable point-of-care devices are improving access in underserved regions. International health programs, diagnostic training initiatives and primary-care infrastructure development continue to support gradual market expansion.

Hemoglobin A1c (HbA1c) Testing Devices Market Segmentations:

By Type of Device

• Laboratory-based Testing Devices
• Point-of-Care (POC) Testing Devices

By End-Use

• Hospitals & Clinics
• Diagnostic Laboratories
• Homecare Settings
• Others

By Technology

• Immunoassays
• Chromatography
• Enzymatic Assays
• Boronate Affinity Chromatography
• High-Performance Liquid Chromatography (HPLC)
• Others

 By Geography

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Competitive Landscape

The competitive landscape in the hemoglobin A1c testing devices market is characterized by the strong presence of leading companies such as Bio-Rad Laboratories, Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Trinity Biotech, Menarini Diagnostics, SEKISUI Medical and HUMAN Diagnostics. These players focus on sustained innovation, portfolio expansion and technological advancement in both laboratory-based and point-of-care HbA1c testing platforms to strengthen their market positioning. The landscape reflects growing investments in automation, assay accuracy enhancement, digital connectivity and interoperability with clinical information systems. Strategic initiatives such as product launches, regulatory approvals, partnerships with healthcare providers and expansion into emerging markets support competitive differentiation. Increasing competition in compact, user-friendly point-of-care analyzers and cost-efficient testing solutions is reshaping pricing dynamics and accessibility.

Key Player Analysis

• Bio-Rad Laboratories Inc.
• Abbott
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers AG
• HUMAN
• Trinity Biotech
• Menarini Diagnostics S.r.l.
• SAKAE CO. LTD.
• Ceragem Medisys Inc.
• SEKISUI MEDICAL CO. LTD.

Recent developments

• In May 2025, Tosoh Bioscience – Diagnostics EMEA launched the GR01 HbA1c analyzer, a compact ion-exchange HPLC-based device from its HLC-723 series that delivers precise results with CVs under 1% and throughput up to 120 tests per hour.
• In January 2025, Korea I.T.S. Co. Ltd. received CES Innovation Awards recognition for QuickGly, the world's first non-invasive real-time HbA1c measurement device connecting via Bluetooth to iOS and Android apps.
• In January 2024, Roche acquired LumiraDx's point-of-care technology, including its HbA1c test, for $295 million to advance rapid, portable diagnostics.

Report Coverage

The research report offers an in-depth analysis based on type of device, end use, technology and geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams and key applications. The report also includes insights into the competitive environment, SWOT analysis, current market trends, and primary drivers and constraints. It examines market dynamics, regulatory scenarios and technological advancements shaping the industry, and provides strategic recommendations for new entrants and established companies.

Future outlook

1. The market will witness sustained growth as routine HbA1c monitoring becomes integral to long-term diabetes management across clinical and primary care settings.
2. Adoption of point-of-care HbA1c testing devices will accelerate with increasing preference for rapid, patient-centric diagnostic workflows.
3. Integration of HbA1c testing systems with digital health platforms and remote monitoring solutions will strengthen data-driven clinical decision-making.
4. Technological advancements will enhance assay accuracy, automation and operational efficiency across both laboratory and decentralized testing environments.
5. Demand for portable and home-based HbA1c testing solutions will rise as self-management of chronic conditions gains wider acceptance.
6. Emerging economies will experience higher market penetration due to expanding healthcare infrastructure and national diabetes screening initiatives.
7. Standardization and quality-assurance programs will become more prominent to ensure consistency across testing methodologies and devices.
8. Strategic collaborations between diagnostic manufacturers and healthcare providers will support innovation and market expansion.
9. Cost-efficient testing platforms will gain traction as healthcare systems prioritize affordability and wider patient access.
10. The market will increasingly align with value-based care models, emphasizing outcome-oriented diabetes monitoring and treatment optimization.